Search Within

Jose T Baselga

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (49)
  2. Journal Article (46)
  3. Research Letter (2)
Groups
  1. GSK Faculty (97)
  2. Human Oncology and Pathogenesis Program (97)
  3. Department of Medicine (94)
  4. Solid Tumor Oncology Division (93)
  5. Breast Medicine Service (78)
  6. Department of Pathology and Laboratory Medicine (68)

More Groups

People
  1. Michael Berger (56)
  2. Sarat Chandarlapaty (48)
  3. David Hyman (45)
  4. David Solit (45)
  5. Ahmet Zehir (29)
  6. Pedram Razavi (27)

More People

Years
  1. 2021 (2)
  2. 2020 (7)
  3. 2019 (8)
  4. 2018 (13)
  5. 2017 (17)
  6. 2016 (17)

More Years

Publications
  1. Cancer Research (23)
  2. Journal of Clinical Oncology (18)
  3. Cancer Discovery (7)
  4. Blood (5)
  5. Cancer Cell (5)
  6. Modern Pathology (4)

More Publications

Publishers
  1. American Association for Cancer Research (32)
  2. American Society of Clinical Oncology (21)
  3. Nature Publishing Group (13)
  4. Cell Press (6)
  5. American Society of Hematology (5)
  6. American Association for the Advancement of Science (4)

More Publishers

Results (97)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling
    Journal Article

    Will, M.; Qin, A. C. R.; Toy, W.; Yao, Z.; Rodrik-Outmezguine, V. ; Schneider, C.; Huang, X.; Monian, P.; Jiang, X.; de Stanchina, E.; more...
    Cancer Discovery (2014)

    Fulltext@MSK | Save
  • Acquired resistance to rapamycin and mTOR kinase inhibitors is mediated by non-overlapping mutations in distinct sites in the mTOR protein
    Meeting Abstract

    Rodrik-Outmezguine, V.; Yao, Z.; Berger, M.; De Stanchina, E.; Klinowska, T.; Barratt, D.; Baselga, J.; Rosen, N.
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS signaling
    Meeting Abstract

    Will, M.; Toy, W.; Yao, Z.; Poulikakos, P.; Rodrik-Outmezguine, V. ; Schneider, C.; Paul, J.; Baselga, J.; Liu, N.; Rosen, N.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
    Journal Article

    Toy, W.; Shen, Y.; Won, H.; Green, B.; Sakr, R. A.; Will, M.; Li, Z.; Gala, K.; Fanning, S.; King, T. A.; more...
    Nature Genetics (2013)

    Fulltext@MSK | Save
  • AACR cancer progress report 2013
    Journal Article

    Sawyers, C. L.; Abate-Shen, C.; Anderson, K. C.; Barker, A.; Baselga, J.; Berger, N. A.; Foti, M.; Jemal, A.; Lawrence, T. S.; Li, C. I.; more...
    Clinical Cancer Research (2013)

    Fulltext@MSK | Save
  • Reactivation of oncogenic signaling through mTOR inhibitors-induced feedback adaptations
    Meeting Abstract

    Rodrik-Outmezguine, V.; Chandarlapaty, S.; Poulikakos, P.; Scaltriti, M.; Baselga, J.; Rosen, N.
    Cancer Research (2012)

    Fulltext@MSK | Save
  • A mechanistic logic for dual targeting of HER2 and PI3K/AKT/mTOR signaling in HER2 amplified breast cancer
    Meeting Abstract

    Chandarlapaty, S.; Rodrik-Outmezguine, V.; Scaltriti, M. M.; Sakr, R.; Will, M.; Giri, D.; Hudis, C.; Baselga, J.; King, T.; Rosen, N.
    European Journal of Cancer (2012)

    Fulltext@MSK | Save